Company
Alkermes INC
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
5
5 still marketed
Novel approvals
2
Approvals since 2021
4
Originals and new uses
Phase 3 trials
34
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Lumryz new use OrphanOct 16, 2024
- Lumryz approved OrphanMay 1, 2023
- Lybalvi approved NovelMay 28, 2021
- Lybalvi approved NovelMay 28, 2021
- Aristada Initio Kit approved Jun 29, 2018
- Aristada new use Jun 5, 2017
- Aristada approved NovelOct 5, 2015
- Vivitrol new use Priority reviewOct 12, 2010
- Vivitrol approved Priority reviewApr 13, 2006
Drugs in development (3)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
Recruiting Phase 3 trials
Largest first.
- A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic HypersomniaPivotal-lookingRecruiting
Alkermes, Inc.Industry
NCT06767683 · 786 participants (planned) · Start Jan 27, 2025 · Primary completion Jun 2030
Drug: ALKS 2680, 4mg; ALKS 2680, 6mg and 4 more · For: Narcolepsy Type 1; Narcolepsy Type 2; Idiopathic Hypersomnia
Sites: Cullman, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 50 sites in all
- Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I DisorderPivotal-lookingRecruiting
Alkermes, Inc.Industry
NCT05303064 · 220 participants (planned) · Start Jun 30, 2022 · Primary completion Sep 2026
Drug: OLZ/SAM; Olanzapine · For: Schizophrenia; Bipolar I Disorder
Sites: Dothan, Alabama; Little Rock, Arkansas; Encino, California · 47 sites in all
- A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2Pivotal-lookingRecruiting
Alkermes, Inc.Industry
NCT07502443 · 176 participants (planned) · Start Apr 22, 2026 · Primary completion May 2027
Drug: ALKS 2680 Dose 1; ALKS 2680 Dose 2 and 2 more · For: Narcolepsy Type 2
Sites: Cullman, Alabama; Phoenix, Arizona; Los Angeles, California · 61 sites in all
- A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)Pivotal-lookingRecruiting
Alkermes, Inc.Industry
NCT07540897 · 150 participants (planned) · Start Aug 13, 2026 · Primary completion Jun 2027
Drug: ALKS 2680 Dose 1; ALKS 2680 Dose 2 and 1 more · For: Narcolepsy Type 1
Sites: Scottsdale, Arizona; Brandon, Florida; Miami, Florida · 53 sites in all
- A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1Pivotal-lookingRecruiting
Alkermes, Inc.Industry
NCT07455383 · 150 participants (planned) · Start Apr 6, 2026 · Primary completion May 2027
Drug: ALKS 2680 Dose 1; ALKS 2680 Dose 2 and 1 more · For: Narcolepsy Type 1
Sites: Cullman, Alabama; Phoenix, Arizona; Tucson, Arizona · 66 sites in all
Marketed drugs (5)
Newest FDA action first.
- Lumryz Sodium Oxybate · 2023
- Lybalvi Olanzapine, Samidorphan L-Malate · 2021
- Vivitrol Naltrexone · 2006
- Aristada Aripiprazole Lauroxil · 2015
- Aristada Initio Kit Aripiprazole Lauroxil · 2018
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.